Enteric fever, primarily caused by Salmonella Typhi and Paratyphi, continues to pose significant health challenges globally. This article provides an updated approach to the effective management of enteric fever in clinical practice, focusing on diagnosis, antimicrobial therapy, and prevention strategies.
Early and accurate diagnosis is crucial for effective management of enteric fever. Blood cultures remain the gold standard for diagnosis, with sensitivity ranging from 40-80%. However, due to limitations such as turnaround time and requirement of laboratory facilities, rapid diagnostic tests (RDTs) like Typhidot and Tubex TF have been developed. These tests, based on detection of specific antibodies, provide results within 2-4 hours and are particularly useful in resource-limited settings.
Due to increasing antimicrobial resistance, the choice of empirical therapy has evolved over time. Fluoroquinolones, once first-line therapy, are now recommended only when susceptibility is confirmed. Current guidelines recommend azithromycin as first-line therapy for uncomplicated cases, with third-generation cephalosporins or carbapenems used for severe or resistant cases. Antimicrobial stewardship programs are essential to monitor resistance patterns and guide therapy.
Prevention of enteric fever primarily involves improving sanitation and access to clean water. Vaccination also plays a key role, with two vaccines currently available: the Vi polysaccharide vaccine and the Ty21a live-attenuated vaccine. The World Health Organization recommends vaccination in endemic areas and for high-risk populations.
In conclusion, the effective management of enteric fever involves a multifaceted approach, including accurate diagnosis, appropriate antimicrobial therapy, and robust prevention strategies. As the landscape of enteric fever continues to evolve with increasing antimicrobial resistance, it is vital for healthcare professionals to stay updated with the latest guidelines to ensure optimal patient care.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation